We are live on ! Find out more
CURX icon

Curanex Pharmaceuticals

2 hedge funds and large institutions have $65.7K invested in Curanex Pharmaceuticals in 2026 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.35% less ownership

Funds ownership: 1.18% → 0.83% (-0.35%)

43% less capital inflows, than outflows

Capital inflows: $36.3K | Capital outflows: $63.5K

82% less funds holding

Funds holding: 11 → 2 (-9)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 9

Holders
2
Holders Change
-9
Holders Change %
-81.82%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
–
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

CURX Hedge Fund Activity: Q3 2026 in Review

2 of the 8,207 institutional investors tracked by Wall St. Rank reported a position in Curanex Pharmaceuticals (CURX) for Q3 2026, worth a combined $65.7K — down 26% from $89K a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of CURX and 0 opened new positions — a net loss of 9 holders — while 0 trimmed existing stakes and 2 added.

The largest buyer was Citadel Advisors, adding an estimated $33.1K. The largest seller was Virtu Financial, exiting entirely with an estimated $14K sold.

  • 2 institutional investors held Curanex Pharmaceuticals (CURX) as of Q3 2026, down from 11 in Q2 2026.
  • Funds reported $65.7K of Curanex Pharmaceuticals stock for Q3 2026, down 26% quarter-over-quarter.
  • 0 funds opened new Curanex Pharmaceuticals positions in Q3 2026 and 9 closed out, a net change of -9 holders.
  • The largest Curanex Pharmaceuticals buyer in Q3 2026 was Citadel Advisors, an estimated $33.1K added.
  • The largest Curanex Pharmaceuticals seller in Q3 2026 was Virtu Financial, an estimated $14K sold.

Based on aggregated 13F filings for Q3 2026.